Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3048 Somatostatin Analogs or Active Surveillance in Sporadic Non-Functioning Pancreatic Neuroendocrine Tumors

Introduction: Non-functioning (NF), sporadic pancreatic neuroendocrine tumors (pNETs) have usually an indolent behavior, but sometimes show an unpredictable aggressiveness. Surgery is the first-choice for localized tumors >2 cm. Unresectable or metastatic lesions expressing somatostatin receptors (SSTRs) are treated with Somatostatin analogs (SSAs). No evidence of SSAs efficacy exists in tumors ≤2 cm, for which active surveillance has been proposed.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Schinzari G, Maiorano B, Rossi E, Bianchi A, Chiloiro S,

Keywords: pNET, non-functioning, sporadic, somatostatin analogs, surveillance,

#1913 Un Unusual Tumor Association in Acromegaly

Introduction: Acromegaly is associated with an increased risk for malignancies. Only a case of pseudomyxoma peritonei with ovarian and appendicular sequential tumors in acromegaly was described

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Bima C, Chiloiro S, Bianchi A, Schinzari G, Inzani F,

Keywords: acromegaly, appendicular tumor,

#1907 Pancreatic Neuroendocrine Tumors in MEN1 Disease: A Monocentrice Longitudinal and Prognostic Study

Introduction: In MEN1+ patients (MEN+), pNETs are considered to be high risk for multiple, malignant and aggressive tumors.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Chiloiro S

Authors: Chiloiro S, Bianchi A, Lanza F, Schinzari G, Bima C,

Keywords: pNETs, MEN, prognosis,

#765 Everolimus Treatment in a Series of Patients with Advanced Neuroendocrine Tumors

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Plastino F, Iacovazzo D, Schinzari G, Barile R, Lugli F,

Keywords: everolimus, prrt,

#303 Pancreatic Metastases from Bronchopulmonary Atypical Carcinoid: An Uncommon Tumor Spreading to a Rare Location

Introduction: We report an uncommon case of pancreatic metastases from a bronchial atypical carcinoid.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Iacovazzo D, Lugli F, Fusco A, Bianchi A, Schinzari G,

Keywords: atypical bronchial carcinoid, pancreatic metastases, SSA, Octreoscan ,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.